Joanna Osmanska, Katriona Brooksbank, Kieran F Docherty, Stacy Robertson, Kirsty Wetherall, Alex McConnachie, Jerry Hu, Roy S Gardner, Andrew L Clark, Iain B Squire, Paul R Kalra, Pardeep S Jhund, Pieter Muntendam, John J V McMurray, Mark C Petrie, Ross T Campbell
AIMS: Subcutaneous (SC) furosemide has potential advantages over intravenous (IV) furosemide by enabling self-administration or administration by a lay caregiver, such as facilitating early discharge, preventing hospitalizations, and in palliative care. A high-concentration, pH-neutral furosemide formulation has been developed for SC administration via a small patch infusor pump. We aimed to compare the bioavailability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of a new SC furosemide formulation with conventional IV furosemide and describe the first use of a bespoke mini-pump to administer this formulation...
January 5, 2024: European Heart Journal. Cardiovascular Pharmacotherapy